Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Sleijfer

Showing results (1-10 of 285) with videos related to

Pageof 29
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 7, 2009
Management of aggressive fibromatosis: can we unravel the maze of treatment options?Stefan Sleijfer
Onkologie|June 7, 2007
Pulmonary alterations during BEP? Always be aware of BIPStefan Sleijfer
The Oncologist|January 31, 2012
Phase II studies in soft tissue sarcoma: time for reappraisalStefan Sleijfer
European Journal of Cancer (Oxford, England : 1990)|March 15, 2006
With a little help from small friends: Enhanced chemotherapeutic effects with imatinibStefan Sleijfer
Cancer|March 13, 2016
Pazopanib for patients with advanced soft tissue sarcomas in a real-life settingStefan Sleijfer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2020
Bridging the Translational Divide in Oncology: <i>In Vivo</i> Testing of Chemo-sensitivityStefan Sleijfer, Martijn Lolkema
Nature Clinical Practice. Oncology|November 3, 2005
Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?Stefan Sleijfer, Gerrit Stoter
Expert Opinion on Pharmacotherapy|March 16, 2013
Pazopanib, a new therapy for metastatic soft tissue sarcomaJaap Verweij, Stefan Sleijfer
The Oncologist|June 3, 2008
Editorial: the long and winding road to better cancer cell-specific therapiesStefan Sleijfer, Erik Wiemer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Dose selection in phase I studies: why we should always go for the topStefan Sleijfer, Erik Wiemer
Pageof 29

Showing results (1-10 of 285) with videos related to

Sort By:
Pageof 29
European Journal of Cancer (Oxford, England : 1990)|October 7, 2009
Management of aggressive fibromatosis: can we unravel the maze of treatment options?Stefan Sleijfer
Onkologie|June 7, 2007
Pulmonary alterations during BEP? Always be aware of BIPStefan Sleijfer
The Oncologist|January 31, 2012
Phase II studies in soft tissue sarcoma: time for reappraisalStefan Sleijfer
European Journal of Cancer (Oxford, England : 1990)|March 15, 2006
With a little help from small friends: Enhanced chemotherapeutic effects with imatinibStefan Sleijfer
Cancer|March 13, 2016
Pazopanib for patients with advanced soft tissue sarcomas in a real-life settingStefan Sleijfer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2020
Bridging the Translational Divide in Oncology: <i>In Vivo</i> Testing of Chemo-sensitivityStefan Sleijfer, Martijn Lolkema
Nature Clinical Practice. Oncology|November 3, 2005
Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?Stefan Sleijfer, Gerrit Stoter
Expert Opinion on Pharmacotherapy|March 16, 2013
Pazopanib, a new therapy for metastatic soft tissue sarcomaJaap Verweij, Stefan Sleijfer
The Oncologist|June 3, 2008
Editorial: the long and winding road to better cancer cell-specific therapiesStefan Sleijfer, Erik Wiemer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Dose selection in phase I studies: why we should always go for the topStefan Sleijfer, Erik Wiemer
Pageof 29